secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001193125-24-258537
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences advances FB102 into celiac trial; Q3 net loss $8.4M
---------------------------------------------------------------------

- Dosing begun in celiac disease trial; topline data expected Q2 2025.
- Phase 1 healthy-volunteer study of FB102 completed with good safety and NK cell reduction.
- Q3 R&D expense $5.9M vs $6.4M YoY; net loss per share $(4.54) vs $(6.57).
- Cash and equivalents $16.4M as of Sept 30, 2024; shares outstanding 1.46M after 1:25 reverse split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312524258537/0001193125-24-258537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312524258537/d892744d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-258537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer